Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due…
| Métrica | PHVS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -64.8% | -39.2% | -25.6% |
| ROA | -58.3% | -30.9% | -27.3% |
| Current Ratio | — | 2.73 | — |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -58.3% | — |
| ✗Flujo de caja operativo positivo | −€137M | −€120M |
| ✗Rentabilidad sobre activos al alza | -58.3% | -46.1% |
| ✓Caja operativa/activos supera al ROA | -45.5% | ROA -58.3% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | — | — |
| ✗Sin aumentar el nº de acciones | 59M | 54M |
| –Margen bruto al alza | — | — |
| –Rotación de activos al alza | — | — |
Pharvaris N.V. cotiza a 27.74 USD y tiene una capitalización bursátil de $1.9B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud